---
title: Reduction of Sweetened Beverages and Intrahepatic Fat
nct_id: NCT01394380
overall_status: COMPLETED
phase: NA
sponsor: University of Lausanne
study_type: INTERVENTIONAL
primary_condition: Obesity
countries: Switzerland
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01394380.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01394380"
ct_last_update_post_date: 2014-06-04
last_seen_at: "2026-05-12T06:12:47.585Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Reduction of Sweetened Beverages and Intrahepatic Fat

**Official Title:** Effects of a Reduction of Sweetened Beverages Consumption in Overweight High Consumers on Cardiometabolic Risk Factors

**NCT ID:** [NCT01394380](https://clinicaltrials.gov/study/NCT01394380)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 29
- **Lead Sponsor:** University of Lausanne
- **Collaborators:** Centre Hospitalier Universitaire Vaudois, Insel Gruppe AG, University Hospital Bern
- **Conditions:** Obesity, Dyslipidemia, Metabolic Syndrome
- **Start Date:** 2011-10
- **Completion Date:** 2014-04
- **CT.gov Last Update:** 2014-06-04

## Brief Summary

The study will enroll 68 overweight male and female subjects with a high (\> 2 3dl-can soda/day) consumption of sweetened beverage per day. After a run-in period of 4 weeks, subjects will be randomized to either a 12-week intervention arm in which sweetened beverages will be replaced by artificially sweetened, calorie-free beverages, or to a control arm. The following measurements will be performed at the end of the run-in period and at the end of the intervention period

* intrahepatic fat concentration
* visceral fat volume
* changes in day-long metabolic profile from baseline(plasma glucose, insulin, and triglyceride concentrations)
* changes in food intake and daily energy, carbohydrate and sugars intake from baseline

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 40 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* gender male or female
* body mass index (BMI) \> 27 kg/m2 consumption of \> 2 3dl-can regular soda/day
* low to moderate physical activity (\< 60 min walking/day; \< 3 exercise session/week

Exclusion Criteria:

* diabetes mellitus
* liver, kidney or heart disease
* any current drug treatment
* contra-indications to MR examination (pacemaker, foreign bodies,etc)
* pregnancy or planned pregnancy
* active weight gain or weight loss (weight change \> 4 kg in the past 12 months)
* consumption of drugs or illicit substances
* consumption of more than 10g alcohol/day
* vegetarians or subjects on special diets
```

## Arms

- **artificially sweetened beverages** (EXPERIMENTAL) — subjects will be required to consume only artificially-sweetened sodas, water, tea or coffee
- **regular sodas** (NO_INTERVENTION) — subjects will continue their usual consumption of sweetened sodas

## Interventions

- **artificially sweetened sodas** (OTHER) — subjects will be allowed unlimited consumption of calorie-free, artificially-sweetened sodas, water, tea or coffee

## Primary Outcomes

- **changes in intrahepatic fat concentration** _(time frame: at the end of run-in and after 12 weeks intervention/control)_ — intrahepatic fat content measured by 1H-MRS

## Secondary Outcomes

- **changes in visceral fat volume** _(time frame: at the end of run-in and after 12 weeks of intervention/control)_
- **changes in day-long metabolic profile** _(time frame: at the end of run-in and after 12 weeks of intervention/control)_
- **changes in food intake from baseline** _(time frame: at the end of the run-in period and after 6, and 12 weeks of intervention/control)_

## Locations (1)

- Clinical Research Center, CHUV, Lausanne, Canton of Vaud, Switzerland

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.clinical research center, chuv|lausanne|canton of vaud|switzerland` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01394380.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01394380*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*